- Home
- EVOK vs PALI Comparison
EVOK vs PALI Comparison
Compare EVOK & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- PALI
- Stock Information
- Founded
- EVOK 2007
- PALI 1996
- Country
- EVOK United States
- PALI United States
- Employees
- EVOK N/A
- PALI N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVOK Health Care
- PALI Health Care
- Exchange
- EVOK Nasdaq
- PALI Nasdaq
- Market Cap
- EVOK 7.7M
- PALI 3.7M
- IPO Year
- EVOK 2013
- PALI N/A
- Fundamental
- Price
- EVOK $3.85
- PALI $1.06
- Analyst Decision
- EVOK
- PALI Strong Buy
- Analyst Count
- EVOK 0
- PALI 2
- Target Price
- EVOK N/A
- PALI $12.00
- AVG Volume (30 Days)
- EVOK 7.2M
- PALI 1.0M
- Earning Date
- EVOK 08-12-2025
- PALI 08-11-2025
- Dividend Yield
- EVOK N/A
- PALI N/A
- EPS Growth
- EVOK N/A
- PALI N/A
- EPS
- EVOK N/A
- PALI N/A
- Revenue
- EVOK $11,594,083.00
- PALI N/A
- Revenue This Year
- EVOK $57.82
- PALI N/A
- Revenue Next Year
- EVOK $59.12
- PALI N/A
- P/E Ratio
- EVOK N/A
- PALI N/A
- Revenue Growth
- EVOK 89.89
- PALI N/A
- 52 Week Low
- EVOK $1.94
- PALI $0.60
- 52 Week High
- EVOK $12.32
- PALI $4.32
- Technical
- Relative Strength Index (RSI)
- EVOK 46.17
- PALI 59.81
- Support Level
- EVOK $4.26
- PALI $0.72
- Resistance Level
- EVOK $4.70
- PALI $1.40
- Average True Range (ATR)
- EVOK 0.43
- PALI 0.15
- MACD
- EVOK -0.15
- PALI 0.03
- Stochastic Oscillator
- EVOK 4.80
- PALI 50.00
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.